These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8424406)

  • 1. Impact of irradiation of residual breast on adjuvant chemotherapy dose intensity.
    Pronzato P; Miglietta L; Rubagotti A; Bertelli G; Queirolo P; Guenzi M; Sertoli MR; Vitale V; Rosso R
    Am J Clin Oncol; 1993 Feb; 16(1):58-60. PubMed ID: 8424406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer.
    Baldini E; Gardin G; Giannessi PG; Evangelista G; Roncella M; Prochilo T; Collecchi P; Rosso R; Lionetto R; Bruzzi P; Mosca F; Conte PF
    Ann Oncol; 2003 Feb; 14(2):227-32. PubMed ID: 12562649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
    Fountzilas G; Dafni U; Gogas H; Linardou H; Kalofonos HP; Briasoulis E; Pectasides D; Samantas E; Bafaloukos D; Stathopoulos GP; Karina M; Papadimitriou C; Skarlos D; Pisanidis N; Papakostas P; Markopoulos C; Tzorakoeleftherakis E; Dimitrakakis K; Makrantonakis P; Xiros N; Polichronis A; Varthalitis I; Karanikiotis C; Dimopoulos AM;
    Ann Oncol; 2008 May; 19(5):853-60. PubMed ID: 18042835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.
    Gérard JP; Héry M; Gedouin D; Monnier A; Goudier MJ; Jacquin JP; Plat F; Cabarrot E; Serin D; Namer M
    Drugs; 1993; 45 Suppl 2():60-7. PubMed ID: 7693424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF and weekly paclitaxel in patients with resected high-risk breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    Papadimitriou CA; Papakostas P; Timotheadou E; Aravantinos G; Bamias A; Fountzilas G
    Cancer Invest; 2008 Jun; 26(5):491-8. PubMed ID: 18568771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen.
    Arriagada R; Spielmann M; Koscielny S; Le Chevalier T; Delozier T; Ducourtieux M; Tursz T; Hill C
    Ann Oncol; 2002 Sep; 13(9):1378-86. PubMed ID: 12196363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
    Eiermann W; Graf E; Ataseven B; Conrad B; Hilfrich J; Massinger-Biebl H; Vescia S; Loibl S; von Minckwitz G; Schumacher M; Kaufmann M;
    Eur J Cancer; 2010 Jan; 46(1):84-94. PubMed ID: 19879750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.
    Erselcan T; Kairemo KJ; Wiklund TA; Hernberg M; Blomqvist CP; Tenhunen M; Bergh J; Joensuu H
    Br J Cancer; 2000 Feb; 82(4):777-81. PubMed ID: 10732745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G; Conrad B; Reimer T; Decker T; Eidtmann H; Eiermann W; Hackmann J; Möbus V; Marmé F; Potenberg J; Stickeler E; Simon E; Thomssen C; Huober J; Denkert C; Alfer J; Jackisch C; Nekljudova V; Burchardi N; Loibl S;
    Cancer; 2015 Oct; 121(20):3639-48. PubMed ID: 26111104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
    Bergh J; Wiklund T; Erikstein B; Lidbrink E; Lindman H; Malmström P; Kellokumpu-Lehtinen P; Bengtsson NO; Söderlund G; Anker G; Wist E; Ottosson S; Salminen E; Ljungman P; Holte H; Nilsson J; Blomqvist C; Wilking N
    Lancet; 2000 Oct; 356(9239):1384-91. PubMed ID: 11052580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.
    Poole CJ; Earl HM; Hiller L; Dunn JA; Bathers S; Grieve RJ; Spooner DA; Agrawal RK; Fernando IN; Brunt AM; O'Reilly SM; Crawford SM; Rea DW; Simmonds P; Mansi JL; Stanley A; Harvey P; McAdam K; Foster L; Leonard RC; Twelves CJ;
    N Engl J Med; 2006 Nov; 355(18):1851-62. PubMed ID: 17079759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dose-intensive chemotherapy and radiotherapy on serum n-terminal proatrial natriuretic peptide in high-risk breast cancer patients.
    Hall KS; Wiklund T; Erikstein B; Holte H; Kvalheim G; Sommer HH; Andersen A; Skovlund E; Bergh J; Hall C
    Breast Cancer Res Treat; 2001 Jun; 67(3):235-44. PubMed ID: 11561769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
    Gogas H; Dafni U; Karina M; Papadimitriou C; Batistatou A; Bobos M; Kalofonos HP; Eleftheraki AG; Timotheadou E; Bafaloukos D; Christodoulou C; Markopoulos C; Briasoulis E; Papakostas P; Samantas E; Kosmidis P; Stathopoulos GP; Karanikiotis C; Pectasides D; Dimopoulos MA; Fountzilas G
    Breast Cancer Res Treat; 2012 Apr; 132(2):609-19. PubMed ID: 22187126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of a dose-density regimen with fluorouracil, epirubicin, and cyclophosphamide on days 1 and 4 every 14 days with filgrastim support followed by weekly paclitaxel in women with primary breast cancer.
    Pietri E; Andreis D; Fabbri F; Menna C; Schirone A; Kopf B; Rocca A; Amadori D; De Giorgi U
    Oncologist; 2015 Mar; 20(3):239-40. PubMed ID: 25637379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
    French Adjuvant Study Group
    J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
    Overgaard M; Hansen PS; Overgaard J; Rose C; Andersson M; Bach F; Kjaer M; Gadeberg CC; Mouridsen HT; Jensen MB; Zedeler K
    N Engl J Med; 1997 Oct; 337(14):949-55. PubMed ID: 9395428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Achieving optimal dose intensity with adjuvant chemotherapy in elderly breast cancer patients: a 10-year retrospective study in a UK institution.
    Oladipo O; Coyle V; McAleer JJ; McKenna S
    Breast J; 2012; 18(1):16-22. PubMed ID: 21999862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidoxorubicin and paclitaxel as primary chemotherapy for T > 3 cm and T4 breast cancer patients.
    Bellino R; Cortese P; Danese S; De Sanctis C; Durando A; Genta F; Grio R; Giardina G; Katsaros D; Massobrio M; Richiardi G; Vicelli R
    Anticancer Res; 2000; 20(6C):4825-8. PubMed ID: 11205227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.